Rimonabant in obese patients with type 2 diabetes

Lancet

Volumn 369, Issue 9561, 2007, Pages 555-

  Randall, Michael D ^a   Kendall, David A ^a   Bennett, Andrew J ^a   O'Sullivan, Saoirse E ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CANNABINOID 1 RECEPTOR; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RIMONABANT; SULFONYLUREA;

APPETITE; DIABETIC OBESITY; DRUG EFFICACY; HUMAN; LETTER; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REPORTER GENE; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 33846939252     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60265-7     Document Type: Letter

References (3)

1. Scheen A., Finer N., Hollander P., Jensen M., Van Gaal L., and for the RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368 (2006) 1660-1672
2. O'Sullivan S., Tarling E., Bennett A., et al. Novel time-dependent vascular actions of Δ9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma. Biochem Biophys Res Commun 337 (2005) 824-831
3. The DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 (2006) 1096-1105